Enlivex Ltd. Ordinary Shares (ENLV)

FairStock Score: 82/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-minded investor, I see Enlivex first as a clinical-stage immunotherapy company, not a proven business. Its Allocetra programs are still in Phase 1/2 or earlier, and with only 34 employees there is little commercial infrastructure yet. I cannot identify a durable moat: no marketed product, no revenue growth figure, and no multi-year filing history — the supplied screen says the Lynch category is none because there are only 0 years of filed annual results. Financial health is mixed. Debt is zero, which is a genuine positive, but trailing free cash flow is -$10.5M and the FCF yield is -4.8%. ROCE is -0.62%, Piotroski F-score is 0/9, and Altman Z-score is 1.92, so the operating picture is weak. Valuation is the puzzle. At the 2026-10-26 close of $2.56 and a $219.5M market cap, the screen shows P/B of 0.02 and a Graham Number of $3,276.94, producing a 99.99% margin of safety, while the 52-week range is $0.19 to $8.11. Those figures are so extreme that I would treat them as clues to inspect, not as a margin of safety. The P/E is 0.00 and the EPS shown is $2,060.70 without a named filing period, so I would not rely on it. Growth is speculative: success depends on trial data, not current earnings. The stock may look statistically cheap, but the business quality and cash generation do not yet support a confident value conclusion.

In plain English: Enlivex is a small experimental medicine company with 34 employees working on a cell-based treatment called Allocetra. The business looks weak today because it is spending more cash than it brings in and has no dependable profit. The share price looks very cheap compared with accounting values, but that alone does not prove the company is a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer